Physician profile

Ryan Card

Modesto, CA

NPI 1538586193

$1,512.96

in general payments reported to CMS, 2019-2025

5 companies · $1,301 in 2025

The $1,301 reported for 2025 was more than what 90% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$961.33
Food and Beverage$477.67
Education$73.96

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Arthrex, INC. $917.61 2025
Legacy Ortho LLC $303.59 2025
Stryker Corporation $137.83 2023-2025 Pro, Aequalis Ascend Flex, Aequalis Perform
Amgen INC. $125.00 2024 Evenity
Cornerstone Medical Associates, INC. $28.93 2024-2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ryan Card

$1,512.96

in general payments reported 2019-2025

Years
2023-2025
Top company
Arthrex, INC.
Context
The $1,301 reported for 2025 was more than what 90% of providers received nationally.

https://glasscript.com/doctor/11561245/ryan-card

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.